Premium-Grade Research Peptides You Can Trust!!

Share

Semaglutide – Clinical

When the peptide Semaglutide is injected, it acts as an agonist to GLP-1 receptors in the body, which helps to stimulate insulin production, reduce glucagon secretion, and delay gastric emptying. This can help to reduce blood glucose levels and further improve glycemic control.

As a result, users can experience reduced appetite which often leads to weight loss. Other known benefits are improved heart, liver, and lung function and the slowing/prevention of Alzheimer’s disease. Improved mood, better sleep quality, and reduced fatigue have also been reported.

Semaglutide should not be used as a quick fix or “miracle” weight loss regimen. However, it can be a helpful aid to establishing healthy eating habits.

Semaglutide is an effective agent for glycemic control and is especially beneficial for those with type 2 diabetes. Treatment with Semaglutide has been shown to reduce A1C levels, fasting glucose levels, and the risk of cardiovascular events in patients with type 2 diabetes (likely due to the fact that Semaglutide helps to reduce blood pressure and LDL cholesterol).

Please note that every individual needs a different dosage of Semaglutide, depending on their body’s need and size, and like all peptides, every individual’s results may vary. Semaglutide may cause mild nausea, diarrhea, constipation, and mild headaches in some cases. If any of these side effects occur, users should decrease their dosage.

Clinically Approved Quality

Enhanced purity standards with third-party verification and GMP certification.

In Stock In Stock 42 available
Total Price $0.00

Recommended Dose: Inject 5 units (500mcg) daily.

Administration: Subcutaneous injection

Timing: On an empty stomach, at least 1 hour before/after eating..

Cycle: Best results occur when taken consistently for 4-12 weeks.

  • Supports healthy aging and longevity pathways
  • May help regulate circadian rhythm and improve sleep quality
  • Supports cellular repair and regeneration processes
  • May support telomere health and cellular longevity
  • Supports immune system balance and resilience
  • May contribute to improved vitality and overall well-being

99% Purity tested via HPLC methods.

Store in a cool and dry place away from children.

What's Included in Each Package?

parcel-icon 4-week-package

1 vial, all supplies included

parcel-icon 12-week-package

2 vials, all supplies included

What's Included in Each Package?

icon 4 Week Package
  • 1 vial of Epitalon 20mg
  • (1) 100-unit syringes for reconstitution
  • (40) 30-unit syringes for injection
  • 1 vial of bacteriostatic water (10mL each)
  • Alcohol prep pads
  • Detailed instruction guide

Using our dosage recommendations listed above, 1 vial will provide 40 500mcg (5 unit) doses, lasting 5.71 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vial can be used, if desired. However, only 28 doses are needed for the 4 week protocol.

icon 12 Week Package
  • 3 vials of Epitalon 20mg
  • (3) 100-unit syringes for reconstitution
  • (120) 30-unit syringes for injection
  • 2 vials of bacteriostatic water (10mL each)
  • Alcohol prep pads
  • Detailed instruction guide

Using our dosage recommendations listed above, 3 vials will provide 120 500mcg (5 unit) doses, lasting 17.14 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vials can be used, if desired. However, only 84 doses are needed for the 12 week protocol.

Exciting Research Findings:

Body Weight Reduction

Published in 2021 in the New England Journal of Medicine, this pivotal trial in 1,961 adults with overweight or obesity (without diabetes) showed that once-weekly subcutaneous semaglutide plus lifestyle intervention led to a mean 14.9% body weight loss at 68 weeks (vs. 2.4% with placebo), with 86% achieving ≥5% loss and superior improvements in cardiometabolic risk factors, establishing it as a game-changer for obesity management.

Read Study

Reduced Risk of Kidney Events

Published in 2024 in the New England Journal of Medicine, this trial in 3,533 patients with type 2 diabetes and CKD showed semaglutide reduced the risk of major kidney events (e.g., kidney failure, ≥50% eGFR decline) and CV death by 24% vs. placebo over 3.4 years, with benefits on eGFR slope and secondary CV outcomes, positioning it as a renoprotective therapy.

Read Study

Customer Reviews

0.0

Based on 0 reviews

Write a Review

Write a Review

Reviews

There are no reviews yet.